The recent development of metabolic imaging methods has been aimed at improving diagnosis of prostate cancer (PCa), both at staging and in biochemical recurrent prostate cancer (BRPCa) when an increase of prostate-specific antigen (PSA) serum values is detected following curative primary treatments as radical prostatectomy or radiation therapy [1,2]. Here, KLK3 is linked to prostate carcinoma.